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Abstract
Pregnancy results in many physiologic changes that can alter the pharmacokinetic profiles of 
medications used during pregnancy. One of the primary factors leading to these pharmacokinetic 
changes is altered activity of drug-metabolizing enzymes. Ondansetron is a substrate of 
cytochrome P450 (CYP) 3A4 (primary metabolic pathway), 2D6, and 1A2, all of which are 
altered during pregnancy. We evaluated the pharmacokinetics of ondansetron at three different 
gestational time points in a 26-year-old, pregnant, Caucasian woman with normal liver and kidney 
function, who was maintained on ondansetron 8 mg administered orally 3 times/day throughout 
her pregnancy. Serial plasma samples were collected from the subject over one 8-hour dosing 
interval at 14, 24, and 35 weeks’ gestation (representing early-, mid-, and late-pregnancy time 
points, respectively). Ondansetron plasma concentrations were determined using liquid 
chromatography-tandem mass spectrometry. Ondansetron area under the plasma concentration–
time curve decreased progressively across gestation (634 ng hr/ml in early pregnancy, 553 ng 
hr/ml in mid-pregnancy, and 387 ng hr/ml in late pregnancy), with a corresponding increase in 
apparent oral clearance (12.6 L/hr in early-pregnancy, 14.5 L/hr in midpregnancy, and 20.7 L/hr in 
late-pregnancy). The decreased area under the plasma concentration–time curve and exposure to 
ondansetron across gestation is likely due to increased activity of CYP3A4 and CYP2D6 during 
pregnancy. We were not able to study this patient during the postpartum period; however, as with 
other CYP3A4 and CYP2D6 substrates, the apparent activities of these isoenzymes are likely 
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return to baseline. To our knowledge, this is the first report to describe ondansetron 
pharmacokinetics across gestation. Additional pharmacokinetic and pharmacodynamic data are 
needed to confirm our results and to evaluate clinical impact; however, in the meantime, clinicians 
should be aware of these pharmacokinetic changes in ondansetron exposure during pregnancy.
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Pregnancy results in many physiologic changes that can alter the pharmacokinetic profiles of 
medications used during pregnancy. Changes in the absorption, distribution, metabolism, 
and elimination of many drugs have been reported during pregnancy.1 One of the primary 
factors leading to changes in pharmacokinetics is altered activity of drug-metabolizing 
enzymes. In pregnancy, the apparent activities of cytochrome P450 (CYP) 3A4, 2D6, and 
2D9, and uridine 5′-diphospho-glucuronosyl transferase (UGT) 1A4 are increased.2, 3 
Conversely, the apparent activities of CYP1A2 and CYP2C19 are decreased during 
pregnancy.2, 3 We evaluated the pharmacokinetics of ondansetron, a substrate for CYP3A4 
(primary metabolic pathway), CYP1A2, and CYP2D64 at three different gestational time 
points in a pregnant woman. This study was conducted in accordance with the Helsinki 
Declaration of 1975 and was approved by the institutional review board.
Case Report
A 26-year-old, pregnant, Caucasian woman was recruited for the study as part of the 
Obstetric-Fetal Pharmacology Research Unit Network project. She had normal liver and 
kidney function and was maintained on ondansetron 8 mg orally 3 times/day throughout her 
pregnancy. Serial blood samples were collected over one 8-hour dosing interval at time 0 
and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 hours after dosing, at 14, 24, and 35 weeks’ gsestation 
(representing early-, mid-, and late-pregnancy time points, respectively). Plasma 
concentrations of ondansetron were measured based on minor modification of a previously 
published liquid chromatography–tandem mass spectrometric assay5 using a Waters 
Separation Module 2695 and a Waters Micromass Quattro micro triple quadrupole mass 
spectrometer (Waters Corp., Milford, MA) using positive electrospray ionization mode. 
Steady-state ondansetron peak plasma concentrations (Cmax) and area under the plasma 
concentration–time curve from 0 to 8 hours (AUC0–8) declined across gestation (Table 1, 
Figure 1). The apparent oral clearance (CL/F) increased across gestation (Table 1).
Discussion
Ondansetron is extensively metabolized in humans. Its primary metabolic pathway is 
hydroxylation, followed by glucuronide or sulfate conjugation.6 Ondansetron is a substrate 
of CYP3A4, CYP2D6, and CYP1A2. Among these phase I enzymes, CYP3A4 is the 
primary enzyme responsible for hydroxylation of ondansetron.4 Given that apparent 
CYP3A4 and CYP2D6 activities increase during pregnancy, we anticipated a change in 
exposure to ondansetron. Consistent with our expectation, the area under the plasma 
concentration–time curve, a measure of systemic exposure of a drug, decreased 
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progressively with time during pregnancy. We were not able to study this patient during the 
postpartum period; however, as with other CYP3A4 and CYP2D6 substrates, the apparent 
activities of these isoenzymes are likely to return to baseline.
Conclusion
To our knowledge, this is the first report to describe ondansetron pharmacokinetics across 
gestation. Additional pharmacokinetic and pharmacodynamic data are needed to confirm our 
results and to evaluate the clinical impact. In the meantime, clinicians should be aware of 
these pharmacokinetic changes in ondansetron exposure during pregnancy that may warrant 
dosing alterations.
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Figure 1. 
Ondansetron plasma concentration–time profile in a pregnant woman at gestational weeks 
14, 24, and 35.
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Table 1
Pharmacokinetic Parameters of Ondansetron
Time Point Cmax (ng/ml) AUC0–8 (ng hr/ml) CL/F (L/hr)
Early pregnancy (14 wks’ gestation) 109 634 12.6
Mid-pregnancy (24 wks’ gestation) 100 553 14.5
Late pregnancy (35 wks’ gestation)   80 387 20.7
Cmax = peak plasma concentration; AUC0–8 = area under the plasma concentration–time curve from 0 to 8 hrs; CL/F = apparent oral clearance.
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